No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension.
Angiotensin II
/ metabolism
Angiotensinogen
/ blood
Animals
Brain
/ metabolism
Brain Stem
/ metabolism
Desoxycorticosterone Acetate
/ administration & dosage
Hypertension
/ chemically induced
Male
Rats, Sprague-Dawley
Renin
/ blood
Renin-Angiotensin System
/ drug effects
Sodium Chloride, Dietary
/ administration & dosage
Valsartan
/ pharmacology
RNAi therapeutics
angiotensin II
angiotensinogen
brain
mineralocorticoid receptor antagonism
salt-sensitive hypertension
Journal
Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731
Informations de publication
Date de publication:
29 01 2021
29 01 2021
Historique:
received:
01
10
2020
revised:
27
12
2020
accepted:
06
01
2021
pubmed:
7
1
2021
medline:
21
8
2021
entrez:
6
1
2021
Statut:
ppublish
Résumé
Brain renin-angiotensin system (RAS) activation is thought to mediate deoxycorticosterone acetate (DOCA)-salt hypertension, an animal model for human primary hyperaldosteronism. Here, we determined whether brainstem angiotensin II is generated from locally synthesized angiotensinogen and mediates DOCA-salt hypertension. To this end, chronic DOCA-salt-hypertensive rats were treated with liver-directed siRNA targeted to angiotensinogen, the angiotensin II type 1 receptor antagonist valsartan, or the mineralocorticoid receptor antagonist spironolactone (n = 6-8/group). We quantified circulating angiotensinogen and renin by enzyme-kinetic assay, tissue angiotensinogen by Western blotting, and angiotensin metabolites by LC-MS/MS. In rats without DOCA-salt, circulating angiotensin II was detected in all rats, whereas brainstem angiotensin II was detected in 5 out of 7 rats. DOCA-salt increased mean arterial pressure by 19 ± 1 mmHg and suppressed circulating renin and angiotensin II by >90%, while brainstem angiotensin II became undetectable in 5 out of 7 rats (<6 fmol/g). Gene silencing of liver angiotensinogen using siRNA lowered circulating angiotensinogen by 97 ± 0.3%, and made brainstem angiotensin II undetectable in all rats (P<0.05 vs. non-DOCA-salt), although brainstem angiotensinogen remained intact. As expected for this model, neither siRNA nor valsartan attenuated the hypertensive response to DOCA-salt, whereas spironolactone normalized blood pressure and restored brain angiotensin II together with circulating renin and angiotensin II. In conclusion, despite local synthesis of angiotensinogen in the brain, brain angiotensin II depended on circulating angiotensinogen. That DOCA-salt suppressed circulating and brain angiotensin II in parallel, while spironolactone simultaneously increased brain angiotensin II and lowered blood pressure, indicates that DOCA-salt hypertension is not mediated by brain RAS activation.
Identifiants
pubmed: 33404046
pii: 227513
doi: 10.1042/CS20201239
doi:
Substances chimiques
Sodium Chloride, Dietary
0
Angiotensinogen
11002-13-4
Angiotensin II
11128-99-7
Desoxycorticosterone Acetate
6E0A168OB8
Valsartan
80M03YXJ7I
Renin
EC 3.4.23.15
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
259-274Informations de copyright
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.